Abstract library

31 results for "Strosberg".
#211 Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors
Introduction: Hepatic transarterial embolization is often recommended for patients with liver-predominant metastatic NETs. Antiangiogenic therapy following embolization may delay tumor revascularization.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#214 Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas
Introduction: The AJCC Cancer Staging Manual (7th edition, 2010) has introduced a novel TNM staging classification for pancreatic NETs. This classification has not yet been validated.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#217 Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors
Introduction: The risk of metastatic spread among patients with early-stage surgically resected pancreatic neuroendocrine tumors has not been well-established.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#218 Survival Analyses of Pancreatic Neuroendocrine Tumors: Contrasting Institutional Databases with Population-Based Registries
Introduction: Prognostic data in pancreatic NETs derives from population-based studies, as well as from institutional databases.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#449 Effective Treatment of a Metastatic Thymic Neuroendocrine Tumor with Capecitabine and Temozolomide: A Case Report
Introduction: Thymic neuroendocrine tumors are rare, with an estimated annual incidence of 0.2 per million. They are generally considered chemoresistant and there have been no reported cases of an objective response to therapy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Vita SarangaPerry
#496 Progression-Free Survival by Prior Somatostatin Analog Use and Primary Tumor Site and Updated Safety Results in Patients with Advanced Neuroendocrine Tumors and a History of Carcinoid Syndrome: A RADIANT-2 Analysis
Introduction: In RADIANT-2, patients (pts) with advanced neuroendocrine tumors (NET) on Everolimus (E, 10 mg/d) + octreotide LAR (O, 30 mg q28d) had clinically meaningful improvement in progression-free survival (PFS) v. placebo (P)+O (16.4 mo v. 11.3 mo, respectively).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Marianne E Pavel
#554 Analysis of the AJCC/ENETS Staging Classification for Midgut Neuroendocrine Tumors
Introduction: The American Joint Committee on Cancer (AJCC) and ENETS have independently introduced a novel TNM staging classification for jejunal-ileal NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Max Feldman
#556 Unresectable Mesenteric Midgut NETs: Are They a Unique Prognostic Category?
Introduction: Patients with lymph-node positive midgut NETs (stage IIIB) represent a heterogeneous group. While some have microscopic lymph node involvement on pathological evaluation, others may develop large, desmoplastic, unresectable tumors in the root of the mesentery.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#792 Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors
Introduction: Pasireotide LAR is a novel SSA with avid binding to SSTR 1, 2, 3 and 5. It has never been investigated in treatment naïve patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Jonathan R Strosberg
Authors: Cives M, Kunz P, Nguyen P, Jump H, ...
#795 Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET): A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS)
Introduction: OCT has shown antitumor activity and significantly prolonged time to tumor progression vs PBO in pts with metastatic midgut NET (PROMID).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Jonathan R Strosberg
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.